Academic Articles & Research Papers

Efficacy comparison of neoadjuvant chemotherapy, chemoradiotherapy, and chemoimmunotherapy in resectable esophageal squamous cell carcinoma: short- and long-term outcomes from a propensity score-matched analysis.

Zhang H, Liang Y, Li C, Wu B et al. • Frontiers in medicine (2026)

PMC PMC Public Access (View-Only) DOI: 10.3389/fmed.2026.1994701 PMC: PMC13728853

View Article » Original Source ↗

The evolution of antigen specific cancer immunotherapy from adoptive cell therapy to personalized cancer vaccines.

Chen Q, Yang S, Yu H, He Y et al. • Discover oncology (2026)

PMC PMC Public Access (View-Only) DOI: 10.1007/s12672-026-05719-1 PMC: PMC13727929

View Article » Original Source ↗

A peptide-based nano-PROTAC synergistically driving ferroptosis-immunotherapy in triple-negative breast cancer.

Wu J, Ji R, Wang L, Zhu Y et al. • Acta pharmaceutica Sinica. B (2026)

PMC PMC Public Access (View-Only) DOI: 10.1016/j.apsb.2026.07.045 PMC: PMC13730232

View Article » Original Source ↗

Surgical stress triggers widespread impairment of NK cell cytotoxicity and cytokine release.

Scaffidi M, Mistry HP, Tanese de Souza C, Alam R et al. • Cancer immunology, immunotherapy : CII (2026)

PMC PMC Public Access (View-Only) DOI: 10.1007/s00262-026-04438-4 PMC: PMC13731816

View Article » Original Source ↗

Viruses in the tumor immune microenvironment: implications for immunotherapy.

Chen X, Ni P, Li W, Wu M et al. • Frontiers in immunology (2026)

PMC PMC Public Access (View-Only) DOI: 10.3389/fimmu.2026.1958538 PMC: PMC13732141

View Article » Original Source ↗

Long non-coding RNA prompts immune-related adverse events risk and immunotherapy response in pan-cancer.

Dong L, Zhang L, Song L, Qu C et al. • iScience (2026)

PMC PMC Public Access (View-Only) DOI: 10.1016/j.isci.2026.118063 PMC: PMC13733469

View Article » Original Source ↗

Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome.

Chen A, Pulido JS, Tonne J, Metko M et al. • Cancer immunology research (2026)

PMC PMC Public Access (View-Only) DOI: 10.1158/2326-6066.CIR-25-1589 PMC: PMC13737429

View Article » Original Source ↗

Real-world evidence of immunotherapy in older adults with advanced non-small cell lung cancer: a retrospective cohort study.

Zhong Y, Wang J, Chen B, Xu Y et al. • Cancer immunology, immunotherapy : CII (2026)

PMC PMC Public Access (View-Only) DOI: 10.1007/s00262-026-04516-7 PMC: PMC13737224

View Article » Original Source ↗

Combination of antibody-drug conjugates with immunotherapy: a new paradigm in cancer treatment.

Lai Y, Qin R, Liu Z • Frontiers in oncology (2026)

PMC PMC Public Access (View-Only) DOI: 10.3389/fonc.2026.1945452 PMC: PMC13735964

View Article » Original Source ↗

Targeting histone methylation with ROS nanoparticles delivering PARPi prodrugs to amplify the stimulation of cGAS-STING for immunotherapy in ovarian cancer.

Sun Y, Li H, Zhang H, Zhang H et al. • Materials today. Bio (2026)

PMC PMC Public Access (View-Only) DOI: 10.1016/j.mtbio.2026.103777 PMC: PMC13738016

View Article » Original Source ↗

The TRIM-cancer paradox: BCG as a programmable vaccine platform and a mechanistic probe for rational immunotherapy design.

Pleshkan VV, Kondratyeva LG, Zinovyeva MV, Bezborodova OA et al. • Frontiers in immunology (2026)

PMC PMC Public Access (View-Only) DOI: 10.3389/fimmu.2026.1930908 PMC: PMC13532213

View Article » Original Source ↗

Equity in Neurotoxicity Care in the Era of Cancer Immunotherapy.

Pereira RM, Budhu JA • Seminars in neurology (2026)

PMC PMC Public Access (View-Only) DOI: 10.1055/a-2936-3979 PMC: PMC13537097

View Article » Original Source ↗

Plasma cell-CD8+ T cell co-enrichment distinguishes immunotherapy-responsive hepatocellular carcinoma subtypes.

Neupane A, Budhu A, Mehrabadi FR, He A et al. • eGastroenterology (2026)

PMC PMC Public Access (View-Only) DOI: 10.1136/egastro-2026-100423 PMC: PMC13536050

View Article » Original Source ↗

Causal AI for cancer immunotherapy: a narrative framework review of target trial emulation, treatment-effect learning and clinical translation.

Zhao X, Liu Z, Yang J, Xie Q et al. • Frontiers in immunology (2026)

PMC PMC Public Access (View-Only) DOI: 10.3389/fimmu.2026.1896755 PMC: PMC13539561

View Article » Original Source ↗

Mechanistic biomarkers for cancer vaccine development: from cancer cell biology to neoantigen-guided precision immunotherapy.

Rusciano D • Frontiers in cell and developmental biology (2026)

PMC PMC Public Access (View-Only) DOI: 10.3389/fcell.2026.1897032 PMC: PMC13542416

View Article » Original Source ↗

Building bridges to immunotherapy: a knowledge-mapping analysis of cervical cancer organoid research.

Tian Y, Chang H, Liu J, Ding W et al. • Frontiers in immunology (2026)

PMC PMC Public Access (View-Only) DOI: 10.3389/fimmu.2026.1788725 PMC: PMC13547482

View Article » Original Source ↗

Ecosystem-matched reprogramming of the tumor-immune microenvironment to overcome cancer immunotherapy resistance.

Wang X, Wang Q, Gao W, He S et al. • Molecular cancer (2026)

PMC PMC Public Access (View-Only) DOI: 10.1186/s12943-026-02748-w PMC: PMC13556080

View Article » Original Source ↗

Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.

Guo X, Wei Y, Miao Z, Ma S et al. • Frontiers in immunology (2026)

PMC PMC Public Access (View-Only) DOI: 10.3389/fimmu.2026.1924506 PMC: PMC13559439

View Article » Original Source ↗

Melanoma in people living with HIV: antigen-presentation loss, spatial immune escape, and inclusive immunotherapy trials.

Giubellino A, Mansini AP • Frontiers in immunology (2026)

PMC PMC Public Access (View-Only) DOI: 10.3389/fimmu.2026.1921391 PMC: PMC13597333

View Article » Original Source ↗

Survival benefit and toxicity trade-offs of first-line chemoimmunotherapy in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized trials.

Zeng X, Chen J • Frontiers in oncology (2026)

PMC PMC Public Access (View-Only) DOI: 10.3389/fonc.2026.1914121 PMC: PMC13597271

View Article » Original Source ↗